

Supplementary Data

Table S1. Demographic, Clinical and Laboratory data of patients with non-severe outcome grouped by period of hospitalization.

	Non-severe COVID 19 First wave	Non-severe COVID 19 Second wave	Non-severe COVID 19 Third wave	P value
N° of subjects	287	599	503	
N° (%) of males	175(61)	362(60,4)	311(61.3)	0.953 ^a
Age, years, median (Q1-Q3)	57(45-66)	62(49-72)	60(51-71)	0.0001 ^b
Days of enrolment after onset of symptoms, median (Q1-Q3)	5(3-8)	6(2-10)	8(5-10)	0.0001 ^b
Charlson comorbidity index, median (Q1-Q3)	2(0-3)	3(1-4)	2(1-4)	0.0001 ^c
N° (%) of subjects with underlying chronic disease				
- With hypertension	108(37.8)	263(44.3)	239(47.2)	0.35 ^a
- With cardio-vascular disease	49(17.1)	167(28.1)	120(23.7)	0.002 ^a
- With diabetes	39(13.6)	125(21)	90(17.8)	0.027 ^a
- With malignancy	17(5.9)	42(7.1)	27(5.3)	0.483 ^a
- With chronic kidney disease	19(6.6)	64(10.8)	22(4.4)	0.0001 ^a
- With chronic obstructive pulmonary disease	37(12.9)	50(8.4)	37(7.3)	0.024 ^a
- With hepatopathy	5(1.8)	20(3.4)	25(5)	0.059 ^a
N° (%) of asymptomatic subjects	28(10.4)	120(20)	53(10.5)	0.0001 ^a
N° (%) of symptomatic patients	240(89.6)	479(80)	454(89.5)	
N° (%) of symptomatic subjects with				
- fever	189(68.7)	325(54.8)	305(60.4)	0.0001 ^a
- cough	109(39.5)	193(32.6)	161(32)	0.078 ^a
- dyspnea	103(37.1)	317(53.5)	356(70.6)	0.0001 ^a
- hypo ageusia	46(21.5)	27(4.6)	15(3)	0.0001 ^a
- hypo-anosmia	42(19.3)	29(4.9)	10(2.0)	0.0001 ^a
- diarrhea	19(8.1)	30(5.1)	22(4.4)	0.100 ^a
- cutaneous lesions	3(1.7)	2(0.3)	3(0.6)	0.138 ^a
Length of hospitalization expressed in days, median (Q1-Q3)	17(13-25)	13(8.5-20)	14(9.5-19)	0.0001 ^c

a, Chi-square test; b, non-way ANOVA; c, Kruskal-Wallis test.

Table S2. Demographic, Clinical and Laboratory data of patients with severe outcome grouped by period of hospitalization.

	severe COVID 19 First wave	severe COVID 19 Second wave	severe COVID 19 Third wave	P value
N° of subjects	105	318	199	
N° (%) of males	74(70.5)	199(62.6)	120(60.3)	0.206 ^a
Age, years, median (Q1-Q3)	73(58-80)	68(57-80)	70(58-81)	0.602 ^b
Days of enrolment after onset of symptoms, Median (Q1-Q3)	6(3-9.5)	6(2-9)	6.5(3-10)	0.760 ^b
Charlson comorbidity index, median (Q1-Q3)	3(1-5)	4(2-5)	3(1-5)	0.070 ^c
N° (%) of subjects with underlying chronic disease				
- With hypertension	55(53.9)	157(49.8)	113(56.8)	0.297 ^a
- With cardio-vascular disease	40(39.2)	114(36.2)	71(35.7)	0.821 ^a
- With diabetes	24(23.5)	87(27.6)	41(20.6)	0.190 ^a
- With malignancy	19(18.6)	26(8.3)	12(6)	0.001 ^a
- With chronic kidney disease	13(12.7)	36(11.5)	19(9.5)	0.667 ^a
- With chronic obstructive pulmonary disease	19(18.6)	48(15.2)	19(9.5)	0.064 ^a
- With hepatopathy	3(2.9)	11(3.5)	4(2.0)	0.616 ^a
N° (%) of asymptomatic subjects	3(3)	29(9.1)	6(3.0)	0.007 ^a
N° (%) of symptomatic patients	97(97)	289(90.9)	193(97)	
N° (%) of symptomatic subjects with				
- fever	48(78.7)	186(58.7)	117(59.1)	0.011 ^a
- cough	32(52.5)	114(36.2)	72(36.4)	0.048 ^a
- dyspnea	37(61.7)	241(75.8)	178(89.9)	0.000 ^a
- hypo ageusia	4(11.1)	10(3.2)	6(3.0)	0.046 ^a
- hypo-anosmia	1(2.8)	8(2.5)	2(1)	0.459 ^a
- diarrhea	5(11.1)	11(3.5)	3(1.5)	0.006 ^a
- cutaneous lesions	0(0)	1(0.3)	1(0.5)	0.894 ^a
Length of hospitalization expressed in days, median (Q1-Q3)	18(10-28)	16(10-24)	14(8-20)	0.006 ^c
Number of patients who died during hospitalization, N°(%)	65(61.9)	104(32.7)	46(23.1)	0.000 ^a

a, Chi- square test; b, non-way ANOVA; c, Kruskal-Wallis test.